Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410) announced a private placement of round 8 unregistered coupon private convertible bond for gross proceeds KRW 32,000,000,000 on September 18, 2020. The coupon rate is 0% and yield to maturity is 1%. The maturity date of bonds is September 22, 2024.

The bonds are 100% convertible into 2,735,744 common shares at a conversion price of KRW 11,697 per share from September 22, 2021 to August 22, 2024. The transaction included participation from returning investor CnPharm Co., Ltd. for KRW 7,000,000,000, Shinhan Investment Corp. for KRW for 4,000,000,000, NH Investment & Securities Co., Ltd. for KRW 1,000,000,000, NH Investment & Securities Co., Ltd. fund for KRW 2,900,000,000, Samsung Securities Co.,Ltd. fund 1 for KRW 2,900,000,000, Samsung Securities Co.,Ltd. fund 2 for KRW 2,800,000,000, Mirae Asset Daewoo Co., Ltd. fund 3 for KRW Mirae Asset Daewoo Co., Ltd. KB Securities Co.,Ltd. fund 4,5 for KRW1,400,000,000, Samsung Securities Co.,Ltd. fund 6,7 for KRW 4,000,000,000, Mirae Asset Daewoo Co., Ltd. fund 8,9 for KRW 2,000,000,000, Mirae Asset Daewoo Co., Ltd. fund 11,12 for KRW for 2,600,000,000, Korea Investment & Securities Co., Ltd fund 13 for KRW 400,000,000, Korea Investment & Securities Co., Ltd. fund 14 for KRW 1,000,000,000.

The subscription date and payment date is September 22, 2020. The transaction has been approved by the board of directors of the company.